These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38254201)
21. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y; BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402 [TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial. Diehl CD; Shiban E; Straube C; Gempt J; Wilkens JJ; Oechsner M; Kessel C; Zimmer C; Wiestler B; Meyer B; Combs SE Cancer Commun (Lond); 2019 Nov; 39(1):73. PubMed ID: 31706337 [TBL] [Abstract][Full Text] [Related]
23. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial). Straube C; Scherb H; Gempt J; Kirschke J; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE BMC Cancer; 2018 Jan; 18(1):15. PubMed ID: 29298660 [TBL] [Abstract][Full Text] [Related]
25. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860 [TBL] [Abstract][Full Text] [Related]
26. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial. König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902 [TBL] [Abstract][Full Text] [Related]
27. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218 [TBL] [Abstract][Full Text] [Related]
28. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
29. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053 [TBL] [Abstract][Full Text] [Related]
30. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma. Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028 [TBL] [Abstract][Full Text] [Related]
31. Optimizing maximum resection of glioblastoma: Raman spectroscopy versus 5-aminolevulinic acid. Herta J; Cho A; Roetzer-Pejrimovsky T; Höftberger R; Marik W; Kronreif G; Peilnsteiner T; Rössler K; Wolfsberger S J Neurosurg; 2023 Aug; 139(2):334-343. PubMed ID: 36681953 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial. Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734 [TBL] [Abstract][Full Text] [Related]
33. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612 [TBL] [Abstract][Full Text] [Related]
34. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
35. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151 [TBL] [Abstract][Full Text] [Related]
37. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study. van Opijnen MP; Broekman MLD; de Vos FYF; Cuppen E; van der Hoeven JJM; van Linde ME; Compter A; Beerepoot LV; van den Bent MJ; Vos MJ; Fiebrich HB; Koekkoek JAF; Hoeben A; Kho KH; Driessen CML; Jeltema HR; Robe PAJT; Maas SLN BMC Med Genomics; 2022 Nov; 15(1):233. PubMed ID: 36333718 [TBL] [Abstract][Full Text] [Related]
38. 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Kamp MA; Felsberg J; Sadat H; Kuzibaev J; Steiger HJ; Rapp M; Reifenberger G; Dibué M; Sabel M Acta Neurochir (Wien); 2015 Feb; 157(2):207-13; discussion 213-4. PubMed ID: 25547719 [TBL] [Abstract][Full Text] [Related]
39. [ Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751 [TBL] [Abstract][Full Text] [Related]
40. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]